Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from MoonLake Immunotherapeutics ( (MLTX) ) is now available.
On November 5, 2025, MoonLake Immunotherapeutics entered into an underwriting agreement with Leerink Partners LLC to issue and sell 7,142,857 Class A ordinary shares at $10.50 per share, aiming to raise $75 million in gross proceeds. The offering, filed with the SEC, is expected to close on November 6, 2025, and includes indemnification provisions for the underwriter against certain liabilities.
The most recent analyst rating on (MLTX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on MoonLake Immunotherapeutics stock, see the MLTX Stock Forecast page.
Spark’s Take on MLTX Stock
According to Spark, TipRanks’ AI Analyst, MLTX is a Neutral.
MoonLake Immunotherapeutics presents a high-risk, high-reward scenario typical for early-stage biotech firms. The strong balance sheet and recent financing provide a solid financial foundation, but the lack of revenue and operational losses weigh heavily on the score. Technical indicators are mixed, and the negative valuation metrics reflect the developmental nature of the company. The significant financing event is a positive catalyst, enhancing the company’s ability to advance its pipeline.
To see Spark’s full report on MLTX stock, click here.
More about MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies for immunological diseases.
Average Trading Volume: 4,475,513
Technical Sentiment Signal: Sell
Current Market Cap: $650.7M
See more insights into MLTX stock on TipRanks’ Stock Analysis page.